ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

QNRX Quoin Pharmaceuticals Ltd

0.686
-0.034 (-4.72%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Quoin Pharmaceuticals Ltd NASDAQ:QNRX NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.034 -4.72% 0.686 0.58 1.00 0.7382 0.68155 0.72 44,426 05:00:04

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

02/05/2024 9:10pm

GlobeNewswire Inc.


Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Quoin Pharmaceuticals Charts.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.

The announcement will provide an operational update regarding the company’s achievements during the quarter, and will detail financial highlights.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:Investor RelationsPCG AdvisoryJeff Ramsonjramson@pcgadvisory.com(646) 863-6341

1 Year Quoin Pharmaceuticals Chart

1 Year Quoin Pharmaceuticals Chart

1 Month Quoin Pharmaceuticals Chart

1 Month Quoin Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock